2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020 | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

« Videos on Science from Koch Institute @MIT

Opinion on the use of Germline Genome Editing in IVF »

2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020

February 21, 2020 by 2012pharmaceutical

2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in REAL TIME

for

http://pharmaceuticalintelligence.com

by

@pharma_BI @AVIVA1950 @MassBio

https://events.bizzabo.com/231443

Wed Aug 26

9:30 AM

9:30 AM – 10:00 AM EDT (30 Min)

Networking

10:00 AM

10:00 AM – 11:15 AM EDT (1 Hour, 15 Min)

Main Stage: Welcome & Changing the Narrative Panel

Mike Nikitas

Master of Ceremonies

Moderator

How the message form Patient is to be shared to get the impact deserved
How do we tell the stories
1/2 or 1/3 would get the Vaccine if it is available NOW

Robert Coughlin

President and Chief Executive Officer

David Lucchino – CEO Frequency Therapeutics Mentor to Robert Coughlin – had two years of record success

MassBio

Speaker

David Lucchino

MassBio’s Immediate Past Board Chair and Co-founder, President and Chief Executive Officer

Frequency Therapeutics

Cancer survival [Millenium & Takeda drug prolonging life for Multiple Myeloma], Therapeutics developer, CEO in Biotech and President and Chief Executive Officer, MassBio
High performance students from suburban school were recruited to get opportunities in biotech

Speaker

Charles Wilson

MassBio’s Board Chair and President and Chief Executive Officer

Unum Therapeutics

Incoming MassBio’s Board Chair and President
Sustainability and opportunities
Fight COVID-19, develop Vaccines
Infrastructure to increase productivity
Equity, diversity inclusion in Biotech

Speaker

Nancy Simonian

Chief Executive Officer

Syros Pharmaceuticals, Inc.

Patient stories and journey that illness is impacting
Joining Pharma because you want to help other people
Foundation need to tell the stories for credibility vs. Pharma as drug developers or Physicians who have a skin in the game of diagnosis and treatment
1st dose of Vaccine 56% while 1/3% Black – will get the vaccine while the black has a disproportional % of COVID-19 effects
Leaders role: National, State level – people will follow Leaders
Dr. Faucci – a role model and treasure
The Focus and opportunities are in Innovations – are insafficient redirect to resonate to People on the Street – open communicate and access

Panelist

Pam Randhawa

Chief Executive Officer

Empiriko

Panelist

drug developers need to have stories from Patients about efficacy of the drug
diagnosis & treatment – tell the story
improve productivity via therapeutics – bringing ill patients back to the labor market impact on Society as a whole
Price and profiting discussion need to change to the good produced
Talking about success is not selling, involve patients to tell stories
Providers need to tell the story of patients – how they perform under a certain treatment
Quit Smoking – brought good stories and the journey of change in life style – dissemination of stories
Vaccines: Speed is increased by operation technology by Government investment – happened due to Pandemic not in regular times
Industry scaling challenge requires explanation to the Public
High health impact vs profits, yet investment needed are coming from the profits

Math needed to be done for drugs selling
Front line to bring drugs – Price too high – explain
comorbidity continues during the Pandemic – two stories need now efforts
Story: What is memorable and relatable
Leadership needs to share the stories of themselves vs talking about Financial
Talk about failing
Be careful with Vaccine to be presented as an industry issue
Strong supporter to encourge volunteers to get the Vaccine
The industry needs Solutions not winners

11:15 AM

11:15 AM – 11:30 AM EDT (15 Min)

Networking

11:30 AM

11:30 AM – 12:00 PM EDT
(30 Min)

Business Breakout: Resilience, Grit, Freedom to Fail…and Pivot

Stuart Peltz

Founder and Chief Executive Officer

PTC Therapeutics, Inc.

Moderator

Barbara Fox

Chief Executive Officer

Rheos Medicines, Inc.

Panelist

Anna Protopapas

President & Chief Executive Officer

Mersana Therapeutics, Inc.

Panelist

11:30 AM – 12:00 PM EDT
(30 Min)

Science Breakout: Lifting the Curtain on R&D to Advance New Drugs Faster

Adam Feuerstein

Senior Writer, Biotech

STAT

Moderator

Katie Ellias

Managing Director

JDRF, T1D Fund = Not-for profit on Diabetes T1D

Foundation works during the years to identify who is at risk
New avenues of Science – in development of therapies
Data sharing, Outreach to Academia
Meetings organized as an Educational day under CDA Pharma and the Foundation – Target of Exploration
What is the Foundation interested in and Pharma collaboration
Transparent with the Foundation due to under CDA
Beta cell Stress vs Stress Companies – targeting Tissue by other companies for other indication – co-develop a plan
accelerate projects to invest in therapeutics then other investors pick up
Immune response is an area of interest – Disease specific educate regulators on candidates
Manufactoring changes for COVID-19

Panelist

John Tallarico

Head, Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research

Novartis

Panelist

Gilead, Takeda and Novaris – Working together on Coronavirus on R&D aspects
Create a Journal of Negative Results – share what was tried but did not work
proprietary targets are under greatest secrecy at Novartis
Novartis Global Scholar Program – Select Academic Institutions for Tech Licensing
Collated from across all parts of Novaris – THIS IS THE PLAY BOOK for the Future and Academis Instituions share with they researches and they submit Intent to collaborate
Can the collaboration for COVID-19 can be ported to OTHER areas of research – attempts will be done because it is rewarding
COVID-19 helped transfer reagents across organization beyond COVID-19 – Silos will remain due to IP channels requiring strict protection
What emerged with OCVID-19 will be preserved vs adandoned like after SAR in 2004

12:00 PM

12:00 PM – 12:15 PM EDT
(15 Min)

Facilitated Networking: Lifting the Curtain on R&D to Advance New Drugs Faster Breakout

BROADCAST

Starts 2 min before the session time

12:00 PM – 12:15 PM EDT
(15 Min)

Facilitated Networking: Resilience, Grit, Freedom to Fail…and Pivot Breakout Session

BROADCAST

Starts 2 min before the session time

12:15 PM

12:15 PM – 12:25 PM EDT (10 Min)

Main Stage: Henri A. Termeer Innovative Leadership Award Presentation

Robert Coughlin

President and Chief Executive Officer

MassBio

Abbie Celniker

Partner

Third Rock Ventures

12:25 PM

Opportunity to innovate
Innovation in Making Therapies
Ex-Genentech –>> Millenium –> Takeda
Mounting the Antibodies response by drugs
1994 in Boston at GI – Genetic Institute – Hemophilia drugs developed – prophylactic treatment
2007 Rock Ventures to see investment in Therapeutics – building teams with diversity is the challenge – expend the landscape to diverse background
Henri A. Termeer created access to diverse work force
This Award calls for taking risks

12:25 PM – 12:45 PM EDT (20 Min)

Networking

12:45 PM

12:45 PM – 1:00 PM EDT (15 Min)

Main Stage: Possible Talk: Patient Stories – Lina Rebeiz’s Road to Medical School

Diagnosis of Acute Intermittent Porphyria (AIP) – is a rare metabolic disorder that is characterized by partial deficiency of the enzyme hydroxymethylbilane synthase (also known as porphobilinogen deaminase). This enzyme deficiency can result in the accumulation of porphyrin precursors in the body.

Lina Rebeiz

First Year Medical Student

1:00 PM

1:00 PM – 1:30 PM EDT
(30 Min)

Business Breakout: From Seed to Series A – Creative Ways to Fun Your Startup

Deborah Palestrant

Partner

5AM Ventures

Moderator

Raymond J. Tesi

President and Chief Executive Officer

ImmuneBio

Panelist

Stephen Kennedy Smith

Principal

Park Agency – Kennedy Enterprises

Panelist

1:00 PM – 1:30 PM EDT
(30 Min)

Science Breakout: Realities of Precision Medicine – How Small is Too Small?

Jennifer Carter

Healthcare Executive, Board member and Entrepreneur

JLC Precision Health Strategies, LLC

Moderator

Rare diseases are different than Cancer – is the kinase different
There are rare cancers
How small is too small

Timothy Yu

Assistant Professor in Pediatrics

Harvard Medical School

Panelist

Neurologist in Genetics department of Children’s Hospital
Rare genetic disorders without Cancer
Genetically subcategorize patients like doing so in a pediatric disease sub-population
A drug was developed for ONE single patient
Nucleotide drugs allow using one platform for several genetics disorders: Same chemical class arranged differently suite of drugs the PK and PD is similar – common approach to treat different patients with same disease but in need for drugs that as slightly different in molecular arrangement
Same drug for multiple indications vs One disease with multiple specific drugs – multiple agents in ONE drug
the only way to make progress in rare disease
EGFR a case for Genetic disease treated by drugs dealing with the genetic disorder
Duchenne is another example EXON 51 vs CRISPR
N-of-1 is the standard achievable if Regulatory will join

Marion Dorsch

Chief Scientific Officer

Blueprint Medicines

Panelist

Rare disease drug — GI 500 patients – FDA allows approval & use after Phase 1
Pediatric population vs Adult
Target the genetic driver
Few hundreds is the current goal

1:30 PM

1:30 PM – 1:45 PM EDT
(15 Min)

Facilitated Networking: From Seed to Series A – Creative Ways to Fun Your Startup

BROADCAST

Starts 2 min before the session time

1:30 PM – 1:45 PM EDT
(15 Min)

Facilitated Networking: Realities of Precision Medicine – How Small is Too Small?

BROADCAST

Starts 2 min before the session time

1:45 PM

1:45 PM – 2:02 PM EDT (17 Min)

Main Stage: Possible Talk: Steve Burton, Determination Through Adversity

Steve Burton

Sports Anchor and Reporter

WBZ-TV

Speaker

Thu Aug 27

9:30 AM

9:30 AM – 10:00 AM EDT (30 Min)

Networking

10:00 AM

10:00 AM – 10:15 AM EDT (15 Min)

Main Stage: Possible Talk: Empowering the Financial Lives of People & Companies with Morgan Stanley

David Lacchino – is praised by MassBio and Executive Team
Encourage diversity, risk taking, affects people and management
as cancer survivor did inspired Frequency Therapeutics
Thanking him for high Bar, impacting patients around the Globe

Jed Finn

Head of Corporate and Institutional Solutions; COO, Wealth Management

Morgan Stanley

Speaker

10:15 AM

Morgan Stanley (MS) – growth faster of peers $50Trillion Asset in Management +$1MM age +50 years old – Emerging segment – moving from Branch to online – direct to client – did not yet developed
In the institutional space – Siliant was acquired a SW cloud-based Canadian for combined Employers and Employees
Education, Retirement Readiness and Wealth Management for Employees via endorsement from Employers
MS offers services to biotech

MS @ works

Benefits for Employers: The C-Suite AND all other employees, lowest fees, Portal soon to be released – How many of the Employees are selleing are holding are buying, shares hold by Employees
Benefits for Employees – Individual Holdings, account reviews and Consulting offered to Employees, Financial Wellness Program to be provided by the Employer is desired by Employees

10:15 AM – 10:45 AM EDT
(30 Min)

Business Breakout: Supporting Regional Growth of the Life Sciences Beyond Cambridge

Mathias Cousin

Managing Director

Deloitte

Moderator

Jim Glasheen

Executive Vice Chancellor

University of Massachusetts Medical School

Panelist

Matt Daniels

Executive Managing Director

JLL

Panelist

10:15 AM – 10:45 AM EDT
(30 Min)

Science Breakout: AI and Drug Discovery: Marrying Data Science with Core Biology

Colin Hill

Chief Executive Officer, President, Chairman, and Co-Founder

GNS Healthcare

Moderator

cellular phynotype, drug target and therapeutics outcome
data is most important technology and Biology which has many interpretations done by different biologists
computer models need one interpretation vs many: Yes no rule bases are needed

Juan Alvarez

AVP, Computational and Structural Chemistry

Merck & Co., Inc.

Panelist

Drug Target identification
Drug Discovery – ML since 1980s
Identify molecules
syntesis prediction
physico space – physiological systems – Transcriptomics, single cell biomarkers, proteomic, metabolomics
evolving proteins
analyzing data
access to compute power data acquisition and storage – High dimensional spaces sample comparison
Find therapies for Humans in the absence of having Humans participating, data on human is BIASED by drugs history
Drugable – identify interventions translatable to Humans pathway-based
Pessimist: Unknowns and changes are inevitable
COVID-19 – some problems can be solved, some are changing environment
collect specimens from melanoma easier than from others

Renée Deehan-Kenney

PhD, VP, QuartzBio

Precision Medicine Group

Panelist

technology enable company clinical data analysis of data clical trials
ML prior knowledge
network biology
drive inside
MOA prioritize indications
Chemistry in developing drugs is complex
Network biology modeling – helps inform chemistry models: Cell line in Mice translation to Human in pancreatic cancer cell line
Pessimistic view: Long way to go end point most of the time are not good, not in my life time
must try encoouraged by published data
love basic research not in Academe

Nora Khaldi

Founder and CSO

Nuritas

Panelist

Math, computer Science
PhD in Drug discovery
Molecular chemistry of Peptide are not used in drug design
integrate toxicity, bioavailability and cell penetration of many peptides,
Identify peptides with very good PK
modulating pathways human perspective vs animal studies – no public sources on humans at the peptide level
synthetic version of plant & food vs natural version for human – efficacy it will have
AI biological data is early while relying on that knowledge
identify drug safe for human is possible I believe AI – take a molecule to humans 99% working in humans AI teated and validated in vitro

10:45 AM

10:45 AM – 11:00 AM EDT
(15 Min)

Facilitated Networking: AI and Drug Discovery: Marrying Data Science with Core Biology

10:45 AM – 11:00 AM EDT
(15 Min)

Facilitated Networking: Supporting Regional Growth of the Life Sciences Beyond Cambridge

11:00 AM

11:00 AM – 11:30 AM EDT (30 Min)

Main Stage: Possible Talk: The Process of Turning What Ifs into Realities through the Life Sciences & State of Possible Award Presentation

Judy Luu

Student

UMass Amherst

Speaker

Robert Coughlin

President and Chief Executive Officer

MassBio

Speaker

Kenneth Anderson

Director, Jerome Lipper Multiple Myeloma Center

Dana-Farber Cancer Institute

Speaker

Multiple Myeloma – 23 drugs approved by FDA
Dana-Farber Cancer Institute with Sanofi collaboration
Foundations stepped forward to study Multiple Myeloma
FDA motivated to help patients Hematologic Division – African Americans
Change paradigm of clinical trials
Geraldine Feraro was a patient at DFCI
Tom Bracow was a patient at DFCI
Ronald Burden – sports
STEM – girls 6th grade to 12 grade
David Lacchino – patient at DFCI

Joe Malarney

Complex Manager and Managing Director

Morgan Stanley

Speaker

11:30 AM

11:30 AM – 12:00 PM EDT (30 Min)

Networking

12:00 PM

12:00 PM – 1:20 PM EDT (1 Hour, 20 Min)

Main Stage: Building a Digital Health Community in Massachusetts and Keynote

Speakers

Naomi Fried

Founder and Chief Executive Officer

Health Innovation Strategies

Moderator

MA best Hospitals: MGH-BWH, Beth Israel-Lahey Clinic, Stuart
BC/BS
Medical Schools
Clusters in Biotech & Digital Health Counsel
Definition of Community changed in the COVID-19 Era
connected is having a new meaning
Service providers will play in building DIGITAL Communities

Stephen Bernstein

Attorney at Law

McDermott Will & Emery LLP

Panelist

Webinars and Zooms allows communication – we will see more innovations – Flatten the World
Greater isolation – US is expected to lead
collaborate is NOW home based – no travel – be creative
Virtual Clinical Trials
Virtual Bench science
Life sciences Products; Deploying a compound, provider responsible for the cost or how the Reimbursement will work
Consumer & Patients: Specialty Pharmacy
collaborations by planning ahead
Virtual will be inevitable if more social distancing will take place

Nick Dougherty

Managing Director

MassChallenge HealthTech

Panelist

Around the World communities, MA Biotech infrastructure
MassChallenge HealthTech: In Mexico, in Israel in Switzerland
Becoming virtual instantly in MARCH 2020
More locations pick up and scale up innovations around the Globe
Financial constraints, solve old problems

Thomas McCourt

President

Ironwood Pharmaceuticals, Inc.

Panelist

GI disease in Patients – My Gi Health started in NIH – symptoms of GI diseases
GI entrepreneurs to build a smart e-Tool to analyze the GI Symptoms
few thousand Patients
Clinical trials many are STUCK – solve problems calls for adoption of all companies to digital platforms
Entrepreneurial spirit in Kendall square took away the prime position of CA Biotech

12:45 PM – 1:05 PM EDT (20 Min)

Main Stage: Keynote: Leading in 21st Century Technologies: Our Products and Our People and Closing Remarks

BROADCAST

Starts 2 min before the session time

Susan Hockfield

President Emerita

Massachusetts Institute of Technology

Keynote

Regional advantage: Collaborations among industry and academia.
Biotech – emerging technologies cusp: Biology convergence with Engineering: sweetspot
resources to be used more productively: Opportunities to include supremely talented people
MA lead by people, by products : Digital Technologies: Physics & Engineering 1.0 to build devices: Electronics industry
21st Century: Partless Biology – DNA, RNA: Biology and Engineering 2.0 Pathways, water,
2.0 Technologies for Diagnostics for COVID-19: is frustrating
Healthcare Cost: Diagnostics too late and too expensively treated
Convergence technology in Cancer: Diagnosis is still two late: Synthetic Biomarkers: Disease specifics enzymes in nano particles used in diagnosis of cancer cells – urine based Test for cancer
Inhaling of particles Volatile organic nano particles can be exhaled for the diagnosis
Future Founders Initiative: Data, Approaches, Implementation
MIT Faculty founding of companies: 56 companies only 2 founded by Women: Inclusion of Women and Black impact GDP and innovations
Bootcamp for Women from the Lab to the Market place
Funding start ups: For Women founded and more women on boards increased to 25% signed by VC Association to track
Draw on more of our TALENTED people as advantages to be drown in the action to invent a better future